SCHEMBL15739719

SCHEMBL15739719

COC(=O)c1ccn2ncc(C)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.46
PIK3CA P42336 2/20 0.46
ATM Q13315 1/20 0.41
KDM4E B2RXH2 4/20 0.41
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
XDH P47989 1/20 0.40
JMJD6 Q6NYC1 1/20 0.40
MAPK1 P28482 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTT P42858 1/20 0.39
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19786566 0.85 EPHB3 (0.44) PIK3CDPIK3CAATMKDM4EMAPT
SCHEMBL15717897 0.84 KDM4E (0.43) PIK3CDPIK3CAATMKDM4ETSHR
SCHEMBL21818039 0.84 CYP1A2 (0.45) PIK3CDPIK3CAATMKDM4EALOX15
SCHEMBL24338017 0.84 EPHB3 (0.44) PIK3CDPIK3CAMAPTCA12CA1
SCHEMBL30204308 0.84 PIK3CD (0.41) PIK3CDPIK3CAATMKDM4EMAPT
SCHEMBL15762377 0.83 HSD17B10 (0.39) KDM4EMAPTALOX15TSHRL3MBTL1
SCHEMBL3082772 0.81 PIK3CD (0.48) PIK3CDPIK3CACA12CA1CA2
SCHEMBL3643070 0.81 SMN1; SMN2 (0.44) PIK3CDPIK3CAKDM4EMAPTTSHR
SCHEMBL24338887 0.80 PIK3CD (0.39) PIK3CDPIK3CAATMKDM4EMAPT
SCHEMBL15762379 0.79 LMNA (0.34) PIK3CDPIK3CAKDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
EP-4337662-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS Bridge Medicines (US) 2024-03-20 EP disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 CN disclosed
WO-2022240830-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES (US) 2022-11-17 WO disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 WO disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 WO disclosed
WO-2014078802-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2014-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 PIK3CD 3258/4885PIK3CA 3503/4885ATM 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.